Burzynski Research Institute, Inc. (BZYR) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.28: the stock has moved about 72% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBurzynski Research Institute, Inc. (BZYR) trades at $0.0002. Burzynski Research Institute, Inc. focuses on researching and developing antineoplaston drugs for cancer treatment. Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for BZYR: BZYR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Burzynski Research Institute, Inc. (BZYR) Healthcare & Pipeline Overview
Burzynski Research Institute, Inc., founded in 1977, is a biotechnology company focused on researching, developing, and marketing antineoplaston drugs for cancer treatment. Operating in the competitive healthcare sector, the company also provides consulting services and produces medical chemical compounds under the Antineoplastons trade name.
What Is the Investment Thesis for BZYR?
Investing in Burzynski Research Institute, Inc. (BZYR) presents a speculative opportunity due to its focus on antineoplaston drugs, a novel approach to cancer treatment. The company's potential value drivers include successful clinical trials and regulatory approvals for its Antineoplastons. However, the company's negative P/E ratio of -2.55 indicates it is not currently profitable. Key risks include the uncertainty of regulatory approval, competition from established cancer therapies, and the challenges of operating in the OTC market. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may also reflect limited trading activity.
Based on FMP financials and quantitative analysis
BZYR Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -2.55 reflects the company's current lack of profitability.
- Beta of 0.28 suggests lower volatility compared to the overall market.
- Focus on antineoplaston drugs represents a unique approach to cancer treatment.
- The company's operations include research, development, production, marketing, and consulting services.
Who Are BZYR's Competitors?
BZYR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.17 | -2.12% | $105M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $6.54 | +0.31% | $8.27M | 32 5-pillar |
| POM Pomdoctor Limited | $1.13 | -3.42% | $9.70M | — |
| MEDS TRxADE HEALTH, Inc. | $2.19 | -1.79% | $9.84M | — |
| KYNB Kyntra Bio, Inc. | $4.50 | -1.75% | $18.2M | — |
| NEUP Neuphoria Therapeutics Inc. | $3.38 | -1.60% | $18.6M | — |
| PETS PetMed Express, Inc. | $1.16 | -4.92% | $26.0M | 33 5-pillar |
| YI 111, Inc. | $3.00 | +4.90% | $26.4M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BZYR's Key Strengths?
Unique antineoplaston therapies.
- Experienced leadership in cancer research.
- Established brand name (Antineoplastons).
- Dedicated focus on alternative cancer treatments.
What Are BZYR's Weaknesses?
Limited financial resources.
- Dependence on a single product line.
- Lack of profitability (negative P/E ratio).
- OTC market listing (lower liquidity and visibility).
What Are the Key Risks for BZYR?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established cancer therapies and larger pharmaceutical companies.
- Regulatory hurdles and uncertainty surrounding the approval of Antineoplastons.
- Adverse results from clinical trials of Antineoplastons.
- Limited financial resources and dependence on a single product line.
- OTC market listing and associated risks (low liquidity, limited disclosure).
What Are BZYR's Competitive Advantages?
- Proprietary Antineoplastons: The company's unique antineoplaston drugs represent a potential competitive advantage.
- Specialized Expertise: The company's expertise in antineoplaston therapies is a valuable asset.
- Established Brand: The Antineoplastons trade name has been in use for several years.
- Intellectual Property: Patents related to antineoplaston formulations and uses.
What Does BZYR Do?
Burzynski Research Institute, Inc., established in 1977 and based in Houston, Texas, is a biotechnology company dedicated to the research and development of antineoplaston drugs for cancer treatment. The company's core focus revolves around its proprietary Antineoplastons, which are medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. These compounds are produced, marketed, and sold by the company. Since its inception, Burzynski Research Institute has been committed to exploring innovative approaches to cancer therapy. The company's activities encompass a range of services, including research, drug development, manufacturing, marketing, and consulting. Its primary product, Antineoplastons, represents a unique approach to cancer treatment, distinguishing it from conventional therapies. The company's operations are primarily based in the United States, with a focus on serving patients and healthcare providers seeking alternative cancer treatment options. Burzynski Research Institute also provides consulting services related to its antineoplaston therapies.
What Products and Services Does BZYR Offer?
- Researches and develops antineoplaston drugs for cancer treatment.
- Produces medical chemical compounds composed of growth-inhibiting peptides.
- Markets and promotes its Antineoplastons trade name products.
- Sells its Antineoplastons products to patients and healthcare providers.
- Offers consulting services related to antineoplaston therapies.
- Focuses on alternative cancer treatment options.
How Does BZYR Make Money?
- Generates revenue through the sale of Antineoplastons.
- Provides consulting services to healthcare providers and patients.
- Invests in research and development of new antineoplaston therapies.
- Markets and promotes its products through various channels.
What Industry Does BZYR Operate In?
Burzynski Research Institute, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant competition. The company's focus on antineoplaston drugs places it in a niche market segment within the broader cancer therapeutics landscape. Competitors include companies like BETRF (Bio-Path Holdings, Inc.), BIXT (Bioxcel Therapeutics, Inc.), BVAXF (Blue Water Vaccines Inc), CPMV (CMP Pharma, Inc.), and FAMDF (Farmaceuticos Argentinos S.A.), all of which are pursuing different approaches to cancer treatment or related therapies. The biotechnology industry is driven by innovation and is subject to stringent regulatory oversight.
Who Are BZYR's Key Customers?
- Cancer patients seeking alternative treatment options.
- Healthcare providers interested in antineoplaston therapies.
- Research institutions involved in cancer research.
- Patients who have exhausted conventional cancer treatments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -160.5%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Burzynski Research Institute, Inc. operates in the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Stanislaw R. Burzynski. BZYR has traded publicly since 1997.
Financial Health
Burzynski Research Institute, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BZYR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
BZYR Latest News
No recent news available for BZYR.
BZYR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BZYR.
Price Targets
Wall Street price target analysis for BZYR.
BZYR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BZYR; grades run from A+ (80-100) to F (below 30).
Leadership: Stanislaw R. Burzynski
Founder and CEO
Stanislaw R. Burzynski is the founder and CEO of Burzynski Research Institute, Inc. He is a physician and scientist who has dedicated his career to researching and developing antineoplaston therapies for cancer. Dr. Burzynski received his medical degree from the Medical University of Lublin in Poland and later moved to the United States to continue his research. He has published numerous scientific papers on antineoplastons and their potential in cancer treatment.
Track Record: Under Dr. Burzynski's leadership, Burzynski Research Institute has developed and marketed Antineoplastons for cancer treatment. He has overseen the company's research and clinical trial programs. He has faced scrutiny and controversy regarding his methods, but has also garnered a dedicated following of patients seeking alternative cancer therapies.
BZYR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Burzynski Research Institute, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and the trading of their stock can be highly speculative. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to less stringent regulatory oversight and reporting requirements.
- OTC Tier: OTC Other
- Limited Disclosure: OTC Other companies often have minimal financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Trading volume is typically very low, leading to wide bid-ask spreads and potential price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight than exchange-listed stocks, increasing the risk of fraud or mismanagement.
- Going Concern Risk: Companies in the OTC Other tier may be facing financial difficulties or have a limited operating history.
- Information Asymmetry: Lack of readily available information can create an uneven playing field for investors.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Longevity of Operations: The company has been in operation since 1977.
- Focus on Research and Development: The company is actively involved in research and development of cancer therapies.
- Scientific Publications: The company has published scientific papers on antineoplastons.
- CEO with Medical Background: The CEO, Stanislaw R. Burzynski, is a physician and scientist.
- Dedicated Patient Following: The company has a dedicated following of patients seeking alternative cancer therapies.
What Investors Ask About Burzynski Research Institute, Inc. (BZYR) — Healthcare
What do analysts say about BZYR stock?
There is currently no available analyst coverage for Burzynski Research Institute, Inc. (BZYR) due to its listing on the OTC Other market and limited financial information. The company's negative P/E ratio of -2.55 indicates it is not currently profitable.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information is available for Burzynski Research Institute, Inc. due to its OTC market listing.
- Analyst coverage is not available for the company.
- The company's future prospects are subject to regulatory approval and clinical trial outcomes.